[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nausea-and-vomiting-postoperative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nausea-and-vomiting-postoperative":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,70,102,125,152,181,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100641306","catheter-redosing-of-autonomic-neural-blockade-after-sleeve-gastrectomy-100641306",false,"NCT07655908","Catheter Redosing of Autonomic Neural Blockade After Sleeve Gastrectomy","Targeted Temporary In Situ Catheter Redosing of Autonomic Neural Blockade for Breakthrough Symptoms After Laparoscopic Sleeve Gastrectomy","Inclusion Criteria:\n\nPatients undergoing elective laparoscopic sleeve gastrectomy with one or more of the following risk factors for breakthrough visceral\u002Fautonomic symptoms:\n\n* Female sex age \\\u003C30 years\n* Prior history of severe postoperative pain after abdominal surgery\n* Prior history of significant postoperative nausea\u002Fvomiting\n* History of opioid intolerance or significant opioid-related adverse effects\n* Allergy\u002Fintolerance to multiple postoperative analgesics\u002Fantiemetics\n* Concomitant hiatal hernia repair\n* Surgeon's judgment of elevated visceral symptom risk based on prior institutional experience\n\nExclusion Criteria:•\n\n* Contraindication to local anesthetics or dexamethasone\n* Chronic opioid dependence\n* Severe psychiatric or cognitive impairment limiting symptom assessment\n* Pregnancy\n* Conversion to open surgery\n* Inability or unwillingness to comply with the postoperative reporting protocol.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Postoperative visceral pain and autonomic symptoms after laparoscopic sleeve gastrectomy may reappear earlier in selected high-risk patients despite standard intraoperative autonomic neural blockade (ANB). Temporary in situ catheter placement permits postoperative ANB redosing when breakthrough visceral symptoms occur.\n\nThis prospective single-arm observational study will evaluate the feasibility, safety, and clinical effectiveness of temporary ANB catheter placement and selective postoperative redosing in high-risk patients undergoing laparoscopic sleeve gastrectomy.",[26,27],"Pain, Acute Post-Operative","Nausea and Vomiting, Postoperative",[29,30,31,32,33],"Autonomic neural blockade","visceral pain","postoperative nausea and vomiting","re-dosing","temporal catheter","NOT_YET_RECRUITING","2026-06-13",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":20},"2026-06-15",{"date":42,"type":20},"2027-02",{"name":44,"class":45},"Universidad Simón Bolívar","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100643201","application-of-multimodal-intervention-in-the-prevention-of-postoperative-nausea-and-vomiting-after-gynecological-laparoscopic-surgery-100643201","NCT07631910","Application of Multimodal Intervention in the Prevention of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery","Transcutaneous Electrical Acupoint Stimulation Versus Sham Stimulation Combined With Dexamethasone Versus Amisulpride for Preventing Postoperative Nausea and Vomiting After Laparoscopic Gynecological Surgery: A Randomized Controlled Factorial Trial","Inclusion Criteria:\n\n* Age 18-65 years;\n* ASA physical status I-II;\n* Scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia;\n* Willing to provide informed consent.\n\nExclusion Criteria:\n\n* Severe cardiac, hepatic, renal, or pulmonary disease;\n* Allergy or skin disease at TEAS application site;\n* Use of antiemetics within 24 hours before surgery; pregnancy or lactation;\n* Vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy);\n* Any condition deemed unsuitable by the investigator.","FEMALE","65 Years",{"count":56,"type":20},212,[23],"1. Background Postoperative nausea and vomiting (PONV) is a common complication after general anesthesia, with an incidence as high as 80% in gynecological laparoscopic surgery. Transcutaneous electrical acupoint stimulation (TEAS) has shown potential as a non-invasive, side-effect-free intervention. Combining pharmacological agents (dexamethasone or amisulpride) with TEAS may provide a synergistic preventive effect, aligning with enhanced recovery after surgery (ERAS) principles.\n2. Study Objectives To evaluate the preventive effect of TEAS on PONV in patients undergoing gynecological laparoscopic surgery, compared with sham stimulation.\n\n   To explore the synergistic effect of dexamethasone or amisulpride when combined with TEAS, and to optimize PONV prevention strategies.\n\n   To assess the impact of multimodal intervention on postoperative recovery quality, length of hospital stay, and patient satisfaction.\n\n   To evaluate the safety of the combined interventions and record any adverse events.\n3. Study Design Design type: 2×2 factorial, randomized, double-blind (participants, outcome assessors, and data analysts blinded to group assignment).\n\n   Randomization: 1:1:1:1 allocation using an online randomization tool.\n\n   3.1 Study Groups Group Intervention A TEAS + Dexamethasone B TEAS + Amisulpride C Sham stimulation + Dexamethasone D Sham stimulation + Amisulpride 3.2 Participants Inclusion criteria: Age 18-65 years; ASA physical status I-II; scheduled for elective gynecological laparoscopic surgery (e.g., ovarian cystectomy, myomectomy) under general anesthesia; willing to provide informed consent.\n\n   Exclusion criteria: Severe cardiac, hepatic, renal, or pulmonary disease; allergy or skin disease at TEAS application site; Receipt of antiemetics within 24 h before surgery; Implanted cardiac pacemaker, cardioverter-;pregnancy or lactation; vulnerable populations (e.g., critically ill, psychiatric disorders, cognitive impairment, illiteracy); any condition deemed unsuitable by the investigator.\n\n   3.3 Interventions A wearable transcutaneous electrical acupoint stimulation (TEAS) wristband will be applied to the P6 (Neiguan) acupoint on the dominant upper extremity. The P6 acupoint is located approximately 3-5 cm proximal to the distal wrist crease, between the tendons of the flexor carpi radialis and palmaris longus. The device integrates the stimulating electrodes within the wristband and does not require external adhesive electrodes.\n\n   TEAS or sham stimulation will be administered at three time points: 30 minutes before surgery and 24 and 48 hours after surgery, with each session lasting 30 minutes.\n\n   Dexamethasone 5 mg (off-label for PONV; approved for inflammatory\u002Fallergic conditions).\n\n   Amisulpride 5 mg.\n\n   3.4 Outcome Measures\n\n   Primary outcomes (0-48 h postoperatively):\n\n   PONV incidence (proportion of patients with nausea, vomiting, or retching). PONV severity (0 = none, 1 = nausea only, 2 = vomiting\u002Fretching, 3 = refractory nausea\u002Fvomiting).\n\n   Secondary outcomes:\n\n   Recovery quality: time to first flatus, first ambulation, hospital stay, bowel function recovery.\n\n   Patient satisfaction: Visual Analogue Scale (VAS, 0-10) and QoR-15 score (0-150).\n\n   Rescue antiemetic use. Management needs for severe PONV. Postoperative pain (VAS at rest and on movement) and opioid consumption. Device-related adverse events (skin irritation, burning, allergy). Drug-related adverse events (e.g., hyperglycemia, hypotension, headache, dizziness, QT prolongation).\n\n   Intraoperative hemodynamics and postoperative complications (e.g., infection, shivering, urinary retention).\n\n   3.5 Follow-up Schedule Postoperative day 1 (24 h): PONV assessment, time to first flatus and ambulation.\n\n   Postoperative day 2 (48 h): PONV incidence\u002Fseverity, rescue medication. At discharge: Satisfaction, hospital stay (via in-person or telephone follow-up).\n4. Sample Size Calculation Assumptions: PONV incidence 50% in control groups, 30% in TEAS groups; two-sided α = 0.05; power = 80%.\n\n   Each main effect level requires \\~93 patients. For a 2×2 factorial design with 1:1:1:1 allocation, this translates to 47 patients per group (total 188). Accounting for a 10% dropout rate, final sample size = 212 patients (53 per group).\n5. Data Management and Confidentiality Electronic Data Capture (EDC) system with unique coding (no direct identifiers).\n\n   Access restricted to authorized research team members.\n6. Informed Consent Written informed consent will be obtained from each participant after full explanation of the study purpose, procedures, risks, and benefits. Participants are informed of their right to withdraw at any time.\n7. Adverse Event Management Dexamethasone-related AEs (transient hyperglycemia, blood pressure fluctuation, gastrointestinal discomfort, rare allergic reactions).\n\nAmisulpride-related AEs (headache, dizziness, constipation\u002Fdiarrhea, QT prolongation, allergic reactions).\n\nTEA-related AEs (local skin discomfort, redness, itching, rare blisters or mild burns).",[27],"2026-06-01",{"date":62,"type":38},"2026-06-08",{"date":64,"type":20},"2026-07-01",{"date":66,"type":20},"2026-10-31",{"name":68,"class":45},"Sir Run Run Shaw Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":69},"100543543","phase-2-aprepitant-treatment-to-prevent-postoperative-nausea-and-vomiting-in-children-undergoing-scoliosis-surgery-100543543","NCT06357234","Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery","A Randomized Controlled Trial Comparing Aprepitant to Standard of Care for Postoperative Nausea and Vomiting Prophylaxis in Children and Adolescents Undergoing Scoliosis Surgery: The APRE-PONV Trial","Inclusion Criteria:\n\n* Posterior Spinal Instrumentation and Fusion (PSIF) for idiopathic scoliosis\n* The fusion must include at least 6 vertebral levels.\n* Children greater than or equal to 8 years old, and less than 19 years old on the day of surgery\n* Weight \\> 40kg - for ease of pharmacy preparation (PONV dose 1mg per kg to max 40mg)\n\nExclusion Criteria:\n\n* Patient\u002F Parent refusal\n* Hypersensitivity to Aprepitant or any ingredient in the formulation or oral solution. (previous allergy or adverse reaction to Aprepitant)\n* Developmental delay as reported by parents\n* Pregnant - Pregnancy test done as standard of care pre-operative\n* Severe systemic disease ASA classification III or greater\n* Concurrent use of any medication with severe interaction with Aprepitant as outlined in product monograph.\n* Neuromuscular or congenital scoliosis\n* Inability to take PO medications","8 Years","19 Years",{"count":80,"type":20},100,[82],"PHASE2","This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).",[85,27,86],"Spinal Fusion","Anesthesia",[88,89,90,91],"pediatric","anesthetic","scoliosis","Aprepitant","RECRUITING","2026-04-22",{"date":95,"type":38},"2026-04-27",{"date":97,"type":38},"2025-03-17",{"date":99,"type":20},"2027-09",{"name":101,"class":45},"IWK Health Centre",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":69},"100612030","phase-3-adding-aprepitant-to-a-multimodal-strategy-for-the-prevention-of-postoperative-nausea-and-vomiting-in-high-risk-outpatient-surgical-patients-100612030","NCT07248280","Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients","Inclusion Criteria:\n\n* 18 years and over, requiring an ambulatory surgery\n* at high risk of post-operative nausea and vomitting defined by at least 3 factors from the Apfel score, calculated just prior to the surgery (female sex; non smoker; previous nausea or vomitting post-op., or motion sickness; expected opioid consumption in postoperative care).\n\nExclusion Criteria:\n\n* Refusal or unable to consent\n* Suspected or documented allergy to aprepitant (emend)\n* Concomitant use of medication interacting via the cytochrome CYP3A4 with aprepitant (pimozide, terfenadine, astemizole, comtadin or cisapride).",{"count":109,"type":20},260,[111],"PHASE3","Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis.\n\nDespite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.\n\nThis study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.",[27,114],"Prevention",[116,91],"Ambulatory care","2026-02-27",{"date":119,"type":38},"2026-03-03",{"date":117,"type":38},{"date":122,"type":20},"2027-01-01",{"name":124,"class":45},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":69},"100601002","autonomic-neural-blockade-in-bariatric-surgery-100601002","NCT07104825","Autonomic Neural Blockade in Bariatric Surgery","Autonomic Neural Blockade During Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial Evaluating Pain and Nausea After Bariatric Surgery","Inclusion Criteria:\n\n* Individuals able and willing to consent and participate in all study activities\n* Adults, ages 18-90\n* All patients with severe obesity undergoing laparoscopic\u002Frobotic gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients taking opiates chronically\n* Patients allergic to study medications\n* Patients with any prior adverse reaction to ingredients included in the block\n* Adults unable to consent\n* Pregnant women\n* Prisoners","90 Years",{"count":134,"type":20},200,[23],"The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain\u002Fnausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.",[138,139,27,140],"Bariatric Surgery Candidate","Pain, Postoperative","Opioid Use",[142],"Autonomic, blockade, bariatric surgery","2026-01-27",{"date":145,"type":38},"2026-01-29",{"date":147,"type":20},"2026-03",{"date":149,"type":20},"2027-12",{"name":151,"class":45},"Endeavor Health",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":69},"100603559","comparison-of-gastric-volume-in-i-gel-and-proseal-laryngeal-mask-airways-100603559","NCT07138092","Comparison of Gastric Volume in I-gel and ProSeal Laryngeal Mask Airways","Comparison of Gastric Insufflation Volume by Ultrasound Using I-gel and ProSeal Laryngeal Mask Airways in Patients Undergoing Urological Surgery","Inclusion Criteria:\n\n* Patients with an ASA (American Society of Anesthesiologists) physical status score of 1 to 3\n* undergoing urological surgeries performed with I-gel or ProSeal LMA\n\nExclusion Criteria:\n\n* Difficult airway\n* Clinically significant upper respiratory tract infection\n* Pre-existing airway disease\n* Pre-existing airway disease\n* History of head and neck surgery\n* Pregnant patients\n* Patients with upper gastrointestinal tract disease","79 Years",{"count":161,"type":20},50,[23],"This study was planned to compare the gastric insufflation volume between i jel and ProSeal laryngeal mask airway (LMA) and its relationship with the oropharyngeal sealing pressure and the incidence of postoperative complications in patients undergoing urological surgery.",[27,165],"Sore-throat",[167,168,169,170],"Gastric insufflation","Ultrasound","Supraglottic airway devices","Oropharyngeal leak pressure","2025-08-15",{"date":173,"type":38},"2025-08-22",{"date":175,"type":20},"2025-08-18",{"date":177,"type":20},"2025-10-10",{"name":179,"class":180},"Diskapi Yildirim Beyazit Education and Research Hospital","OTHER_GOV",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100587395","frequency-of-occurrence-and-risk-factors-of-postoperative-nausea-and-vomiting-during-elective-c-section-under-spinal-anesthesia-with-preventive-medication-100587395","NCT06927830","Frequency of Occurrence and Risk Factors of Postoperative Nausea and Vomiting During Elective C-section Under Spinal Anesthesia With Preventive Medication","Incidence and Risk Factors of Postoperative Nausea and Vomiting (PONV) During Elective C-Section Under Spinal Anesthesia With Multimodal Antiemetic Prophylaxis","Inclusion Criteria:\n\nAny patient requiring elective caesarean section under spinal anesthesia, at a gestational age \\>37 weeks of amenorrhea in the context of a single-fetal pregnancy.\n\nExclusion Criteria:\n\nFailure to understand the French language; Contraindication to locoregional anesthesia; Nausea and\u002For vomiting in the 24 hours preceding the procedure; Type 1 or type 2 insulin-requiring non-gestational diabetes; Allergy or contraindication to one of the products used in the usual management protocol; Severe preeclampsia; Height \\\u003C150 cm",{"count":189,"type":20},400,"OBSERVATIONAL","The aim of this study is to learn about the incidence and risk factors of nausea and vomiting during planned caesarean section under spinal anesthesia.\n\nThe main question it aims to answer is : What are the incidence and risks factors of postoperative nausea and vomiting (NV) during planned caesarean section under spinal anesthesia with administration of intrathecal morphine and multimodal antiemetic prophylaxis ?\n\nPatients who will be managed according to the standard protocol in use in the department will have to answer specific questions about NV in the post-interventional recovery room and on 2 further visits in the first 24 hours post-caesarean section.",[27,193,194,195],"Cesarean Delivery","Spinal Anesthesia","Antiemetic Therapy","2025-04-14",{"date":198,"type":38},"2025-04-15",{"date":200,"type":38},"2025-03-19",{"date":202,"type":20},"2026-04",{"name":204,"class":45},"University of Liege",2,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":69},"100574560","the-effect-of-cold-steam-application-on-nausea-and-vomiting-100574560","NCT06760871","The Effect of Cold Steam Application on Nausea and Vomiting","The Effect of Cold Steam Application on Nausea and Vomiting After Laparoscopic Abdominal Surgery: Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing abdominal surgery under general anaesthesia,\n* Admitted to the general surgery ward after surgery,\n* Who volunteered to participate in the research,\n* No mental disability,\n* 18 years of age,\n* Literate,\n* Accepting random selection,\n* without Turkish communication problems,\n* No preoperative oncological treatment,\n* undergoing elective surgery,\n* Postoperatively without a nasogastric catheter,\n* with an operation time \\\u003C4 hours,\n* Laparoscopic surgery performed,\n* No postoperative nausea and vomiting or mild\u002Fmoderate nausea,\n* Patients with ASA score 1, 2 or 3 were determined as inclusion criteria.\n\nExclusion Criteria:\n\n* Severe nausea or active vomiting prior to administration,\n* Migraine, vertigo, etc. who may experience nausea and vomiting due to vestibular disease, pregnancy,\n* COPD, asthma, etc. with respiratory problems,\n* Not accepting the application of cold steam,\n* Not accepting random selection,\n* Those with a history of chemotherapy or radiotherapy before surgery,\n* Patients who underwent sudden movement changes (bed change, patient transfer, etc.) during the data collection period (0 to 2nd hour),","110 Years",{"count":215,"type":20},88,[23],"The aim of this study was to determine the effect of cold vapour applied to patients undergoing laparoscopic abdominal surgery primarily on nausea and vomiting and secondarily on antiemetic requirement, patient satisfaction and thirst.\n\nH1: Cold steam application after surgical intervention has a decreasing effect on postoperative nausea.\n\nH2: Cold steam application after surgical intervention has a decreasing effect on postoperative vomiting.\n\nH3: Cold steam application after surgical intervention reduces the need for antiemetic drugs.\n\nH4: Cold steam application after surgical intervention has a satisfactory effect on reducing nausea and vomiting.",[27],"2025-01-06",{"date":221,"type":38},"2025-01-07",{"date":223,"type":20},"2025-01-15",{"date":225,"type":20},"2025-12-30",{"name":227,"class":45},"Trakya University"]